Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,674,710
Summary
U.S. Patent 5,674,710, granted on October 7, 1997, to Bristol-Myers Squibb, covers a pharmaceutical composition involving specific compounds for therapeutic use. This patent plays a notable role in the landscape of kinase inhibitors, particularly in oncology and autoimmune indications. Its claims primarily focus on the chemical structure of the compounds, their pharmaceutical compositions, and methods of treatment. The patent landscape surrounding this patent includes subsequent patents citing its claims, modifications and improvements of the original compounds, and related patents covering further therapeutic methods involving these compounds.
This report provides a comprehensive review of the patent's scope, claims, and the broader patent landscape, emphasizing strategic insights valuable for stakeholders involved in drug development, licensing, or patent litigation.
1. Introduction to U.S. Patent 5,674,710
Patent Title: Novel Substituted Pyrazolopyrimidines and Related Compounds and Their Use in Treating Diseases
Inventors: Robert S. Nelson, et al.
Assignee: Bristol-Myers Squibb
Filing Date: August 17, 1994
Issue Date: October 7, 1997
Patent Abstract
The patent discloses substituted pyrazolopyrimidines with specific chemical structures characterized by their potential kinase inhibitory activity. These compounds are claimed to be useful for treating diseases mediated by abnormal kinase activity, including cancers, autoimmune diseases, and inflammatory conditions.
2. Scope and Claims of U.S. Patent 5,674,710
2.1 Core Chemical Structure
The patent claims a class of compounds with the core structure:
| Element |
Description |
| Core |
Pyrazolopyrimidine ring system |
| Substituents |
Varied at specific positions to alter kinase activity and pharmacokinetics |
The general structure as outlined in Claim 1 is:
A compound of the formula [chemical structure], wherein R1, R2, R3, R4, R5, R6, and R7 are defined by various possibilities, including hydrogen, alkyl groups, halogens, and cyclic groups.
2.2 Main Patent Claims
| Claim Type |
Content |
Scope |
| Claim 1 |
Broad composition claim |
Covers a wide range of substituted pyrazolopyrimidines with specified substituents at designated positions. |
| Claims 2-10 |
Specific compounds |
Narrow claims covering particular combinations of substituents with verified biological activity. |
| Claims 11-15 |
Pharmaceutical compositions |
Claims inclusive of dosage forms, excipients, and combination therapies. |
| Claims 16-20 |
Methods of therapy |
Claims covering methods for treating diseases involving kinase inhibition, including cancer and autoimmune disorders. |
2.3 Key Limitations and Scope
- Promotes a broad genus of compounds, providing extensive coverage for chemical variations.
- Claims encompass both the compounds and their use in pharmaceutical preparations.
- Focused on treating kinase-related diseases, a prominent strategy in cancer and immunology.
2.4 Critical Analysis of the Claims
- Breadth: Claim 1's broad scope provides powerful patent protection, covering a large chemical space.
- Specificity: Narrower claims specify preferred compounds, strengthening enforceability for key embodiments.
- Potential Challenges: Due to broadness, claim validity may face prior art challenges pending the evolution of kinase inhibitor patents.
3. Patent Landscape Analysis
3.1 Patent Citations and Influences
| Citation Type |
Examples |
Relevance |
| Backward Citations |
U.S. Patent 4,920,209 (disclosing similar heterocyclic compounds) |
Foundational chemical scaffolds |
| Forward Citations |
Multiple subsequent patents covering kinase inhibitors, e.g., US 6,027,877 (BMS, 2000) |
Indicating the patent's influence on neighboring innovations |
3.2 Subsequent Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
| US 6,014,987 |
Pyrazolopyrimidine derivatives as kinase inhibitors |
1998 |
Bristol-Myers Squibb |
Refinements of structures |
| US 6,168,927 |
Method for treating cancer using kinase inhibitors |
1999 |
Bristol-Myers Squibb |
Therapeutic methods |
| US 6,297,278 |
Combination therapies involving pyrazolopyrimidines |
2000 |
Bristol-Myers Squibb |
Drug combinations |
3.3 Patent Expiry and Lifecycle
- The original patent expired in 2014, based on a 20-year term from filing.
- Subsequent continuation and divisional patents extended protection in specific jurisdictions.
- The landscape now includes generic competition, with patent challenges and licensing activities centered on narrower claims.
3.4 Patent Strategies and Limitations
- Claim Narrowing: Later patents often focus on specific compounds with distinct substitutions, potentially avoiding patent infringement.
- Method Claims: Focus on therapeutic methods to extend protection beyond chemical compounds.
- Combination Patents: Covering drug combinations involving these compounds broaden IP coverage.
4. Comparative Analysis with Similar Patents
| Attribute |
U.S. Patent 5,674,710 |
US 6,168,927 (related) |
Scope and Use |
| Core Scaffold |
Pyrazolopyrimidine |
Same |
Both cover kinase inhibitors |
| Claim Breadth |
Broad |
Narrower |
Patent 5,674,710 covers broad genus |
| Therapeutic Areas |
Cancer, autoimmune |
Similar |
Overlapping in kinase inhibition scope |
| Filing Date |
1994 |
1998 |
Original patent established fundamental chemistry |
5. Strategic Implications
5.1 For Patent Holders and Licensees
- The broad claims of the '710 patent provided initial protection for early compounds.
- Its expiration opened opportunities for generics, but subsequent patents protect leading compounds and methods.
- Licensing strategies can focus on narrow, specific compounds or methods still under patent.
5.2 For Competitors
- Careful analysis of claim scope aids in designing non-infringing molecules.
- Infringement avoidance involves understanding the chemical variations covered by subsequent patents.
- Patent landscape mapping indicates areas of innovation and potential freedom-to-operate.
5.3 For Litigation and Patent Challenges
- Broad claims mean possible invalidity arguments based on prior art.
- Narrower claims offer enforceability but may limit scope.
- Challenges may target the novelty or non-obviousness of specific substitutions.
6. Conclusion
U.S. Patent 5,674,710 established a foundational platform for kinase inhibitor development within the pharmaceutical industry. Its broad chemical claims and therapeutic scope enabled extensive subsequent innovation while providing solid initial patent protection. The patent landscape reveals a dynamic field with strategic filings extending, narrowing, or modifying the original claims to sustain patent exclusivity. Stakeholders must analyze claim language critically, monitor subsequent patents, and evaluate freedom to operate based on these insights.
7. Key Takeaways
- Broad Scope: The original patent’s comprehensive chemical claims facilitated wide-reaching protection for pyrazolopyrimidine derivatives.
- Patent Expiry and Competition: The patent expired in 2014; recent patents focus on specific compounds and methods, influencing current market entry strategies.
- Landscape Dynamics: Continuing patent activity reflects ongoing innovation in kinase inhibitors; understanding the interconnected patent network is crucial to strategic planning.
- Litigation and Patent Clearance: Due to broad claims, patent validity challenges are possible, requiring detailed prior art searches.
- Future Directions: Innovation now shifts toward targeted therapies with narrower claims, combination modalities, and personalized medicine approaches.
8. FAQs
Q1: What are the primary therapeutic applications associated with compounds claimed in U.S. Patent 5,674,710?
Answer: The main applications include treating cancers, autoimmune diseases, and inflammatory disorders through kinase inhibition.
Q2: How does the broadness of the patent's claims impact the development of similar compounds?
Answer: Broad claims threaten generic competitors; however, subsequent patents with narrower claims may allow for non-infringing derivatives.
Q3: Are there any notable legal disputes related to U.S. Patent 5,674,710?
Answer: No publicly documented litigations directly challenge this patent; however, its expiration has reduced infringement concerns.
Q4: How does the patent landscape influence licensing activities?
Answer: Companies leverage patent family networks to negotiate licensing, especially for specific compounds or combinations covered by subsequent patents.
Q5: What strategies are used to circumvent this patent in drug discovery?
Answer: Developing molecules with modified core structures outside the claim scope, or focusing on methods and formulations not covered, are common strategies.
References
[1] U.S. Patent 5,674,710. "Novel Substituted Pyrazolopyrimidines and Related Compounds and Their Use in Treating Diseases". Inventors: Nelson et al. (1997).
[2] Patent citations from USPTO database and related literature.
[3] Bristol-Myers Squibb patent family filings and extensions.
This report provides a strategic, detailed understanding for professionals analyzing drug patent protections, underlying innovation, and competitive positioning.
